

Neuland Laboratories Limited
11th floor (5th level), Phoenix IVY Building,
Plot No.573A-III, Road No.82, Jubilee Hills,
Hyderabad-500033, Telangana, India.

CONTACT
040 6761 1600 / 6761 1700
neuland@neulandlabs.com
neulandlabs.com



August 5, 2026

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai – 400 001

The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai – 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sir/Madam,

Sub: Investors/Analysts Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the presentation to the Investors/ Analysts on the Financial Results of the Company for the quarter ended June 30, 2026.

The presentation is also being uploaded on the website of the Company at www.neulandlabs.com.

This is for your information and records.

Thanking You,

Yours sincerely,
For **Neuland Laboratories Limited**

Sarada Bhamidipati
Company Secretary

Encl: As above

Neuland Laboratories Limited

Investor Presentation
Q1FY27

SAFE HARBOUR

Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "plan", "contemplate", seek to", "future", "objective", "goal", "likely", "project", "should", "potential", "will pursue", and similar expressions of such expressions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other risks. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.

Table of Content





Q1FY27 Highlights

SAHARSH DAVULURI, CEO & MD

"Q1 FY27 was broadly in line with our expectations with encouraging performance from both CMS & GDS businesses and represents a good start to the year. While Commercial Products contributed to most of the revenue, we are seeing exciting developments in terms of the pipeline projects. The depth of customer conversations today is significantly stronger, and we are increasingly engaging on broader capability-led discussions rather than individual projects alone. Internally our focus now is on ensuring that we deliver consistently, build customer confidence and establish the foundation for long-term partnerships. Even as we have invested significantly over the last three years and all our significant Capex projects are proceeding according to plan, I believe the intensity of our investments will further increase based on the opportunities that available to us. "



Q1FY27 Business Overview



CMS

CMS revenues driven by commercial molecules.

Growth in new projects orders which will be delivered over the course of this and next financial years.

Traction from Innovators with peptides molecules in pipeline.

GDS

In Prime segment Ezetimibe and Mirtazapine were the key molecules. Ezetimibe likely to drive growth of the Prime segment.

Specialty business driven by Aripiprazole Sterile, Donepezil and Apixaban.



Financial Highlights


Working capital days of sale at 84 days in Q1FY27 as against 137 days in Q4FY26, mainly on account of decrease in receivables.

Capex outflow of Rs. 122 Cr in Q1FY27.


Q1FY27 Financial Highlights




Total Income
(Rs. Cr)




EBITDA
(Rs. Cr)



PAT
(Rs. Cr)



EPS
(Rs.)




Financial Highlights

- Total Income for Q1FY27 at Rs. 650.1 crore (116.3% YoY)
- EBITDA for Q1FY27 at Rs. 231.1 crore (448.2% YoY)
- EBITDA Margin for Q1FY27 at 35.5% (increased by 2150 bps YoY)
- PAT for Q1FY27 at Rs. 147.4 crore (975.0% YoY)
- Net Debt stood at Rs. (308.5) crore as at Q1FY27 end compared to Rs. (164.7) crore as at Q1FY26 end and Rs (156.8) crore as at Q4FY26 end


Key Balance Sheet Metrics




Current Ratio(x)




ROCE %



Fixed Asset Turnover (x)



Debt to Equity (x)




Particulars (Rs Cr)	Mar-23	Mar-24	Mar-25	Mar-26	Jun-26
Shareholder's Funds	988.4	1267.5	1,517.8	1,865.9	2,013.2
Net Debt*	63.0	-32.6	-228.7	-156.8	-308.5
Tangible Assets (including CWIP)**	511.2	575.4	698.3	1,002.9	1,116.9
Working Capital	463.0	525.4	440.6	773.0	600.5

*Net debt includes investment in Mutual Fund in previous years.

**Tangible assets includes investment property in previous years.

Key Operating Metrics Q1FY27




- CMS business caters to Innovator customers on an exclusive basis, developing and manufacturing APIs/Intermediates in line with rigorous customer expectations hence is highly concentrated in terms of customers
- Specialty segment works on complex products and technologies, hence has a focused approach towards select customers

CMS – Revenue Split & Number of Active Projects




Rs. Cr

YoY Movement



Rs. Cr

QoQ Movement



No. of active CMS projects

Q1 FY27	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Grand Total
API	15	13	13	5	4	9	59
Intermediate	2	10	7	8	3	10	40
Grand Total	17	23	20	13	7	19	99

Q1 FY26	Pre-Clinical	P-1	P-2	P-3	Pre-Reg/Reg	Commercial	Grand Total
API	15	14	13	5	4	9	60
Intermediate	5	8	7	4	4	10	38
Grand Total	20	22	20	9	8	19	98

Q1 FY25	Pre-Clinical	P-1	P-2	P-3	Development	Commercial	Grand Total
API	8	8	12	3	8	8	47
Intermediate	9	4	11	4	6	10	44
Grand Total	17	12	23	7	14	18	91

Q1 FY24	Pre-Clinical	P-1	P-2	P-3	Development	Commercial	Grand Total
API	14	5	10	4	8	8	49
Intermediate	6	4	6	4	7	11	38
Grand Total	20	9	16	8	15	19	87

- Pre-clinical to P-3: Neuland generates revenue by process research & development as well manufacturing quantities for clinical trials
- *Pre-Reg/Reg: Phase-3 complete; Molecules filed but not yet commercial (Earlier labelled as 'Development') or where customer working towards adding Neuland as a second source for a commercial molecule
- Commercial: Neuland generates revenues by manufacturing APIs for commercial novel molecules for innovators
- Steady trend in molecules transitioning from clinical phases to commercialisation resulting in increase in revenue from commercial products



Company Overview


Company Overview



Established in

1984

40 years in API manufacturing
and development



Total reactor volume of

**12,26,000
Liters**



Facilities
Inspected by
USFDA, EMA,
PMDA, Rx-360,
TGA, KFDA,
ANVISA, WHO



Supported 3 NDA
filings and 18 IND
filings by supplying
APIs and CMC
documentation

Commercially
Manufactured novel
APIs and Intermediates
for brands



Expertise in manufacture of
Deuterated molecules, Cyanation,
Solution and Solid phase peptides.

Cyclic peptides and PEGylated
peptides, Hydrogenation,
Bromination, Chiral molecules
manufacture, Cryogenic reactions,
Enzymatic reactions, Synthetic
portion of fermented molecules,
Micronization (D90 <5 micron)




3 cGMP Manufacturing facilities
Chemical R&D Labs
Peptide Labs
Analytical R&D Labs
Process Safety Labs
Hydrogenation Lab



~2272

Employees,
406 in R&D

Key Facts



Board Of Directors



**Dr. Davuluri
Rama Mohan Rao**
Executive Chairman



D. Sucheth Rao
Executive Vice
Chairman



D. Saharsh Rao
Chief Executive Officer
& Managing Director



**Mr. Prasad
Raghavan Menon**
Independent
Director




**Mr. Homi Rustam
Khusrokhhan**
Independent
Director



**Dr. Ravi Shankar
Gopinath**
Independent
Director



**Ms. Pallavi Joshi
Bhakru**
Independent
Director



Mr. Sugata Sircar
Independent
Director



**Dr. Mauricio
Futran**
Non-Executive
Director


Key Milestones

Our Journey




Successfully cleared 18 USFDA inspections

Multiple audits passed with Zero observations



Our Global Presence*



Manufacturing and Development partner to customers in over 80 Countries globally

* - Based on End-Market revenues – 3M FY27

Manufacturing Facilities Overview



UNIT - I

Bonthapally, Hyderabad 256 kL



UNIT - II

Pashamylaram, Hyderabad 389 kL



UNIT - III

Gaddapotharam, Hyderabad 581 kL



Year of
Establishment

1986

1994

2017



Blocks

Block - 1, 2, 3, 4, H, kL & S

Block-1, 2, 3, FC, NMSM, Mini plant(A&B)

Block - 1, 2, 4, 5, 6, 7 & 8



Hydrogenation
Reaction Volume

7.5 kL

6 kL

5 kL



Solvent Recovery
System

100 kL/D

20 kL/D

50 kL/D



Cryogenic
Reaction Volume

25 kL

17 kL

15 kL



Regulatory

USFDA, EDQM, CFDA, PMDA, Et al.

USFDA, EDQM, PMDA, ANVISA, Et al.

Desktop Inspection by USFDA in 2020;
USFDA May 2023, ANVISA (Brazil) 2022

Adding capacities for backward integration and new business

State-of-the-art R&D Centre



Infrastructure

- 15 Development Labs with space for expansion
- 70 Fume hoods
- Analytical Labs
- Dedicated kilo Lab for Scale up
- Dedicated Labs for Peptides
- Approvals for DSIR, Govt. of India and USFDA
- R&D Team of 406 People
- 600 MHz NMR

Neuland is set to open its new state-of-the-art research and development center, spanning across 140,000 square feet, in Hyderabad's Genome Valley



Neuland's R&D facility had been inspected by USFDA in February 2016 with zero observations

Significant R&D achievements

- Several NCE APIs added in NDA or commercial stage drugs
- Support for multiple APIs each year in Phase 2 and Phase 3 clinical candidates

Generic API business

- 1010+ DMFs filed
- 300+ API processes developed
- 204+ patents filed

Regulatory Filings



75

DMFs with
USFDA



33

Filings with
Health Canada



10

Japanese
DMF filed



17

China DMF
filed



26

Filings with
KFDA Korea



28

Filings with
TGA



291

ROW filings
including
Turkey, Mexico,
Brazil etc.



~499

EUDMF filings
across Germany,
France, Poland,
Italy etc.



31

CEPs received
for different
products



1010+

Filings till date

**** The numbers on this slide reflect the number of filings, the number of active filings could vary as geographic filings are merged and changes in product portfolio**

Financial Highlights FY2017-2026



Rs. Crore

Particulars	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	FY2026
Total Income	588.9	533.7	670.3	766.6	953.0	953.2	1,200.9	1,571.1	1,497.3	2,053.1
EBITDA	106.9	54.6	61.4	105.3	162.5	144.3	281.1	474.5	342.8	603.4
<i>EBITDA Margin</i>	<i>18.1%</i>	<i>10.2%</i>	<i>9.2%</i>	<i>13.7%</i>	<i>17.1%</i>	<i>15.1%</i>	<i>23.4%</i>	<i>30.2%</i>	<i>22.9%</i>	<i>29.4%</i>
PAT	46.4	11.8	16.1	15.9	80.3	63.5	163.1	299.6	259.4	363.1
<i>PAT Margin</i>	<i>7.9%</i>	<i>2.2%</i>	<i>2.4%</i>	<i>2.1%</i>	<i>8.4%</i>	<i>6.7%</i>	<i>13.6%</i>	<i>19.1%</i>	<i>17.3%</i>	<i>17.7%</i>
EPS	41.6	10.6	12.8	12.4	62.6	49.5	127.1	233.5	202.2	283.0
Current Ratio (x)	1.3	1.2	1.4	1.4	1.5	1.6	1.7	2.1	2.4	2.1
ROCE (%)	15.9%	5.0%	4.7%	8.9%	13.5%	9.7%	21.3%	32.8%	17.9%	26.1%
Fixed Asset Turnover (x)	3.8	3.2	2.9	2.3	2.4	2.1	2.7	3.1	2.3	2.6
Debt to Equity (x)	0.7	0.5	0.3	0.3	0.1	0.2	0.1	0.1	0.1	0.1

- FY26 revenues showed a significant increase due to the scale up in key molecules in the CMS business. The increase in revenues impacted other financial metrics as a result of operating leverage.
- Revenue was impacted in FY2018 as a result of mismatch in capacity vs orders. EBITDA margins in FY19 & FY20 were impacted as a result of spike in RM prices, which led Neuland to actively work towards Supply chain de-risking before the COVID19 pandemic
- ROCE was impacted by due to acquisition of unit III in FY2018 which was commercialized in FY2021. Unit 3 utilisation levels have recently started ramping up and momentum is expected to continue



Business Strategy



Neuland Strategy Framework





Our Businesses

Generic APIs (GDS)



- We are a preferred service provider in the manufacturing of Active Pharmaceutical Ingredients (APIs)
- Have developed processes for over 100 APIs with a strong portfolio of complex molecules
- **Process Investigation Department (PID)** majorly helps our customers to meet their price pressures by way of cutting their total cost of ownership in developing an API thereby achieving excellence in Process development
- API manufacturing heritage of over 40 years
- Flexible 100g to hundreds of tons capacity
- Non-competitive advantage (does not compete in finished formulation)
- Worldwide customer base in 80+ countries
- Proven project management systems
- Impeccable EHS record




**Facilities &
Capacity**




Three US FDA and
cGMP compliant
manufacturing facilities

100 APIs across 10
diverse areas



Total capacity of the reactor volume
12,26,000 liters

CDMO Services (CMS)



Chemistry & manufacturing capabilities


Synthetic portion of fermented molecules	Carbohydrate chemistry
Deuterated molecules	Cyclic and PEGylated peptides
Peptides in solid, solution phase & hybrid technology	Organometallic carbon-carbon bond formation
Cyanation, hydrogenation, bromination, cryogenic	Heterocyclic compounds
Steroidal bile acids & vitamin D derivatives	Chiral compounds manufacturing



Facilities & Capacity



Three US FDA and cGMP compliant manufacturing facilities




Total capacity of the reactor volume
12,26,000 liters



Shareholder Information

Shareholding Details



Share Information (as on 30th June 2026)	
NSE Ticker	NEULANDLAB
BSE Ticker	524558
Market Cap (Rs. Cr)	23,902.34
% free-float	67.38%
Free-float market cap (Rs. Cr)	16,105
Shares Outstanding	1,28,29,889
3M Average Daily Traded Volume (ADTV) (Shares)*	60,073
3M Average Daily Traded Value (In Rs. Cr)*	99
Industry	Pharmaceuticals

* Source: BSE & NSE



Annexure



Profit & Loss Snapshot (Standalone)

Particulars	Q1FY27	Q1FY26	YoY (%)	Q4FY26	QoQ (%)
Total Income	650.1	300.6	116.3%	788.7	-17.6%
EBITDA	231.1	42.1	448.2%	319.4	-27.6%
EBITDA Margin	35.5%	14.0%	2150 bps	40.5%	-500 bps
Profit Before Tax	197.5	17.4	1036.7%	287.0	-31.2%
PBT Margin	30.4%	5.8%	2460 bps	36.4%	-601 bps
Profit After Tax	147.4	13.7	975.0%	212.5	-30.6%
PAT Margin	22.7%	4.6%	1811 bps	26.9%	-423 bps
EPS (Rs.)	114.9	10.7	975.0%	165.6	-30.6%

Revenue & PBT trend



Rs Cr



* Q1FY25 and Q3FY25 includes exceptional item of profit on investment property of Rs. 20.6 crores and Rs. 55.8 crores respectively



Our Vision

We are creating a healthier world through sustainable practices, trusted partnerships, and agile collaboration

Our Values



Innovation

Innovative in everything we do



Transparency

Transparent and open in our communication



Agility

Agile in our execution



Accountability

Accountable for our delivery



Empathy

Empathy in all our interactions

Vision and Values

Sustainability Framework: ESG commitment & Goals (1/3)



Environment

Focus area	Our commitments	Key ESG goals (included in Balance Scorecard)
Emissions and climate change	- Reduce both direct (Scope 1 & 2) and indirect (Scope 3) emissions. - Adopt cleaner technologies and improve energy efficiency.	- FY 2033-34: 58.8%* reduction in Scope 1 & 2 emissions (FY 2023-24 baseline) - FY 2049-50: Achieve Net Zero in absolute emissions (subject to residual ~10%) - FY 2033-34: 63.8% *reduction GHG emission reductions in indirect Scope 3 emissions (FY 2023-24 baseline) - FY 2049-50: Achieve net-zero emissions across operations and value chain (subject to residual ~10%)
Water management	Improve water use efficiency and move toward water neutrality.	- FY 2034-35: Achieve 25% water neutrality - FY 2049-50: Achieve 100% water neutrality
Effluent and waste	Maintain Zero Liquid Discharge (ZLD) status for our manufacturing operations, reduce solid waste, and ensure 100% co-processing	- Maintain Zero Waste to Landfill 100% co-processing of hazardous waste - Maintain ZLD status of effluents
R&D and innovation	Drive sustainable R&D and technology innovation to reduce environmental impact.	Adoption of Green Chemistry and aim to achieve Zero solvent carbon footprint

Sustainability Framework: ESG commitment & Goals (2/3)



Social

Focus area	Our commitments	Key ESG goals (included in Balance Scorecard)
Occupational health and Safety	Strive for zero harm environment across all operations	- Maintain Zero Fatality - Maintain Nil Long-term Injury - Frequency Rate (LTIFR)
Diversity and Inclusion	- Promote equal opportunity and build a more inclusive workplace - Promote well being and a safe place to work	- FY 2029-30: 10% women in management - FY 2029-30: 16% of all hirings will be women
Community well-being	Support health, education, and livelihood initiatives for underserved communities.	Ensure Planned social impact investments on well-being of neighboring communities is maintained, while expanding the reach of CSR to larger population

Sustainability Framework: ESG commitment & Goals (1/3)



Governance

Focus area	Our commitments	Key ESG goals (included in Balance Scorecard)
Product Quality and Regulatory compliance	Strong Quality Culture	Maintain 100% compliance across GMP operations
Business Continuity & Risk Management	Build resilience through enterprise-wide risk management, crisis readiness, and business continuity plans	Strengthen crisis management and business continuity capability
Digitalisation	<i>Leverage digital tools for transparency, efficiency, and data driven decision-making</i>	<i>>90% of business process digitised across key functions by FY29-30</i>
Sustainable Supply Chain	Build a responsible and transparent supply chain that supports sustainability goals	Sustainable Supply Chain roadmap with clearly-defined milestones

Glossary



Term	Description
Active Pharmaceutical Ingredient (API)	Any substance that is intended for incorporation into a finished drug product and is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body
Biologic	Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues.
Commercial molecules	Molecules where Neuland is manufacturing for commercial use after the product has been approved
Custom Manufacturing Solutions (CMS)/ Contract Development and Manufacturing Organization (CDMO)	Develop and manufacture pharmaceutical ingredients and intermediates in line with customer expectations.
Development Molecules	Projects where Phase-3 is over, and molecules have been filed but not yet commercial.
DMF	A Drug Master File (DMF) is a submission to the Food and Drug Administration (FDA) that may be used to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs
GDS	Generic Drug Substance (GDS) segment which includes Prime products and Specialty products
International Council for Harmonisation (ICH) Guidelines	Harmonisation project involving regulatory authorities and pharmaceutical industry to improve efficiency of new drug development and registration processes
New Chemical Entity (NCE)	NCE is granted to “a drug that contains no active moiety that has been approved by FDA in any other application”
Peptides	Peptides are sequences of molecules called amino acids. Peptides of precise sequences may occur naturally in the body, but they may also be produced synthetically or using recombinant DNA technology in bacteria and other living systems. These molecules are used to treat a variety of diseases

Term	Description
Pipeline drugs	Drugs (small or large molecule) under development by a manufacturer
Prime APIs	The prime products which typically include mature APIs with relatively higher competition in API space have historically contributed more than 70% of the total business.
Specialty/ Niche APIs	Molecules in the API space which are complex in nature and are in the nature of ‘high value’ added products and Neuland’s focus has been to develop these molecules from laboratory scale to large commercial quantities
Preclinical study	Preclinical studies take place in animals before any testing in humans is done.
Phase I clinical trial	Researchers test an experimental drug or treatment in a small group of people for the first time.
Phase II clinical trial	The experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase III clinical trial	The experimental study drug or treatment is given to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.
Small molecule products	A drug that can enter cells easily because it has a low molecular weight. Once inside the cells, it can affect other molecules, such as proteins, and may cause cancer cells to die. This is different from drugs that have a large molecular weight, which keeps them from getting inside cells easily. Many targeted therapies are small-molecule drugs
USFDA	The US Food and Drug Administration is responsible for protecting the public health by ensuring the safety, efficacy, and security of drugs, biological products, and medical devices

Source: FDA.gov, Neuland

Thank you

For further information contact

IR Desk
Neuland Labs
Contact: +91 40 6761 1600
Email: ir@Neulandlabs.com

Runjun Jain/ Minakshi Machutre
EY IR
Contact: +91 22 6192 2000
Email: Runjhun.Jain1@in.ey.com / Minakshi.Machutre@in.ey.com